Needham raised the firm’s price target on Taysha Gene Therapies (TSHA) to $10 from $8 and keeps a Buy rating on the shares after the FDA granted breakthrough therapy designation to TSHA-102 for the treatment of Rett syndrome.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TSHA:
- Positive Outlook for Taysha Gene Therapies: Buy Rating Affirmed with FDA Support and Breakthrough Designation
- Taysha Gene Therapies Gains FDA Breakthrough Designation
- Taysha Gene Therapies announces FDA BTD to TSHA-102
- Taysha Gene Therapies announces inducement grant under Nasdaq listing rule
- Taysha Gene Therapies’ Earnings Call: Progress Amid Challenges